Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $63.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.41M
Average 0.43M
FBIO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Fortress Biotech, Inc.NASDAQ: FBIO
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $16.04M rose 22.1% year over year, ahead of the +14.5% change in trailing-twelve-month revenue. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $76.75M (+21.3%) for the fiscal year ending Dec 2026, a step up from the +9.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $16.04M-0.3% QoQ
- Last fiscal yearDec 2025
- $63.26M+9.7% YoY
- LTMMar 2026
- $66.16M+14.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +22.1% | +11.5% | -10.6 pp |
| 1 year | +9.7% | +21.3% | +11.6 pp |
| 3-year CAGR | -5.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 63.26M USD
- Year-over-year change
- +9.7%
- 4-year CAGR
- -2.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.26M | +9.7% |
| FY2024 | 2024-12-31 | 57.68M | -31.8% |
| FY2023 | 2023-12-31 | 84.51M | +11.6% |
| FY2022 | 2022-12-31 | 75.74M | +10.1% |
| FY2021 | 2021-12-31 | 68.79M | — |
Revenue vs competitors
How FBIO compares with its peers on the latest reported figures
- FBIO's LTM Mar 2026 revenue of $66.16M is the 2nd highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +14.5% is the 3rd highest of 4, against a peer median of +106.7%.
- Over three fiscal years its annual growth of -5.8% compares with a peer median of -3.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $255.61M | +439.3% | +1204.0% | |
| LTM Mar 2026 | $66.16M | +14.5% | -5.8% | |
| LTM Mar 2026 | $9.14M | +106.7% | -8.6% | |
| LTM Apr 2026 | $1.8M | -24.8% | -0.7% | |
| LTM Jun 2024 | $815.75K | — | -6.2% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding FBIO) | $0 | +106.7% | -3.4% | |
Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.79M | 75.74M | 84.51M | 57.68M | 63.26M |
| Cost of Revenue | 32.08M | 30.78M | 22.89M | 20.88M | 20.92M |
| Gross Profit | 36.71M | 44.97M | 61.62M | 36.8M | 42.34M |
| Gross Margin | 53.4% | 59.4% | 72.9% | 63.8% | 66.9% |
| Research & Development | 128.87M | 134.88M | 106.07M | 56.88M | 11.9M |
| Selling, General & Admin | 86.84M | 113.66M | 90.98M | 87.73M | 96.4M |
| Operating Expenses | 225.25M | 248.53M | 203.96M | 147.18M | 112.56M |
| Depreciation & Amortization | 6.79M | 9.35M | 6M | 4.46M | 4.66M |
| EBITDA | (146.17M) | (193.69M) | (135.72M) | (104.49M) | (20.17M) |
| EBITDA Margin | -212.5% | -255.7% | -160.6% | -181.2% | -31.9% |
| Operating Income | (188.54M) | (203.56M) | (142.34M) | (110.38M) | (70.22M) |
| Operating Margin | -274.1% | -268.8% | -168.4% | -191.4% | -111.0% |
| Interest Income | 649K | 1.4M | 3M | 2.68M | 2.49M |
| Interest Expense | 15.31M | 13.64M | 12.52M | 9.93M | 8.71M |
| Other Income / Expenses | 24.19M | (9.9M) | (11.29M) | (10.16M) | 36.69M |
| Income Before Tax | (164.35M) | (213.46M) | (153.63M) | (120.54M) | (33.54M) |
| Pre-Tax Margin | -238.9% | -281.8% | -181.8% | -209.0% | -53.0% |
| Income Tax Expense | 473K | 449K | 521K | 312K | (620K) |
| Net Income | (64.7M) | (86.58M) | (60.64M) | (46M) | 6.82M |
| Net Margin | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% |
| EPS (Basic) | (11.85) | (14.55) | (8.47) | (2.69) | (0.07) |
| EPS (Diluted) | (11.85) | (14.55) | (8.47) | (2.69) | (0.07) |
| Weighted Avg Shares | 5.45M | 5.93M | 8.11M | 20.78M | 27.9M |
| Weighted Avg Shares (Diluted) | 5.45M | 5.93M | 8.11M | 20.78M | 279.02M |
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.